Experimental autoimmune Goodpasture's disease: A pathogenetic role for both effector cells and antibody in injury  by Dean, Elizabeth G. et al.
Kidney International, Vol. 67 (2005), pp. 566–575
Experimental autoimmune Goodpasture’s disease: A
pathogenetic role for both effector cells and antibody in injury
ELIZABETH G. DEAN, GABRIELLE R.A. WILSON, MING LI, KRISTY L. EDGTTON, KIM M. O’SULLIVAN,
BILLY G. HUDSON, STEPHEN R. HOLDSWORTH, and A. RICHARD KITCHING
Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria,
Australia; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee; and Department of
Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
Experimental autoimmune Goodpasture’s disease: A patho-
genetic role for both effector cells and antibody in injury.
Background. Goodpasture’s disease [antiglomerular base-
ment membrane (GBM) glomerulonephritis] is a classic au-
toimmune disease and the only organ-specific autoimmune
renal disease in which the antigen is well described. The im-
portance of antibodies against the non-collagenous domain of
the a3 chain of type IV collagen [a3(IV)NC1] is well estab-
lished. However, observational human studies and studies in
experimental systems also imply a role for cell-mediated effec-
tor injury.
Methods. Active experimental autoimmune glomerulone-
phritis (EAG) was induced by immunization with a3-
a5(IV)NC1 heterodimers in B cell intact C57BL/6 mice and
B cell (l chain-deficient) mice. Passive disease was induced by
transferring sera from B cell intact and B cell deficient mice
with EAG to RAG-1−/− mice (that lack adaptive immunity).
Histologic and functional injury was studied.
Results. Despite the absence of B cells and immunoglobulin
in B-cell–deficient mice, histologic and functional injury devel-
oped in mice immunized with a3-a5(IV)NC1, with T cells and
macrophages in glomeruli. Injury occurred to a similar degree
to that found in B-cell–intact mice. Transfer of sera from B-
cell–intact mice with EAG containing antibodies (but not from
B-cell–deficient mice with EAG) to RAG-1−/− mice induced
linear immunoglobulin deposits on the glomerular basement
membrane (GBM) and pathologic proteinuria.
Conclusion. Both cell-mediated and humoral effectors are
capable of inducing renal injury in EAG. Given the similarity
of the disease-initiating antigen in this model to the antigen
in human anti-GBM glomerulonephritis, similar overlapping
mechanisms are likely to operate in human disease.
Many forms of glomerulonephritis are caused by im-
mune responses to self or foreign antigens that may be
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intrinsic to or planted in the glomerulus, or may induce
immune systemic immune complex formation. Human
Goodpasture’s disease [antiglomerular basement mem-
brane (GBM) glomerulonephritis] is a classic form of
glomerulonephritis where autoimmune responses are di-
rected against a component of the GBM, the noncol-
lagenous domain of the a3 chain of type IV collagen
[a3(IV)NC1] [1, 2]. Unlike most other forms of glomeru-
lonephritis, the antigenic target has been well defined.
Studies in human and experimental autoimmune anti-
GBM glomerulonephritis have advanced our knowledge
of how tolerance to self antigens is lost and how immune
renal injury develops.
The glomerulus is potentially vulnerable to injury from
a number of different immune effectors, directed by dif-
ferent immune responses [3]. Humoral mechanisms of
injury, including immunoglobulins, can cause injury by
recruiting macrophages and neutrophils by Fc receptors
[4, 5] or activating the complement cascade. In addi-
tion, antibody alone in the absence of complement or
cells can induce injury by directly disrupting the size and
charge selectivity of the GBM [6–8]. Cell-mediated pro-
cesses, driven by effector CD4+ [9, 10] or CD8+ cells
[11], having the potential to recruit macrophages in a
delayed-type hypersensitivity (DTH)-like fashion, can
also effect injury in glomerulonephritis, including in the
absence of immunoglobulin [10]. Different experimen-
tal systems have demonstrated roles for both humoral
and cell-mediated processes in different circumstances.
In experimental crescentic glomerulonephritis induced
by planted antigens, cell-mediated DTH-like mechanisms
are important [9, 12], while in other models, for exam-
ple in MRL/lpr mice, B cells seem essential [13] but cell-
mediated effectors also play a role [14].
Goodpasture’s disease is considered a classic antibody-
mediated autoimmune disease. The seminal experiments
of Lerner, Glassock, and Dixon [15] demonstrated
that injury could be induced by transfer of heterolo-
gous antibody from humans to new world monkeys,
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plasmapheresis is standard treatment for human anti-
GBM glomerulonephritis [16] and many studies in human
disease have implicated humoral immunity in Goodpas-
ture’s disease [1, 2]. Other studies in experimental models
of experimental autoimmune glomerulonephritis (EAG)
have provided evidence that cell-mediated processes can
induce injury in this disease, including those using bursec-
tomized chickens [17], murine EAG similar to the current
studies [18, 19], as well as experimental manipulations
[11] and transfer studies in EAG in Wistar-Kyoto rats
[20]. These studies, as well as progress toward defining a
T-cell epitope using peptides or peptide sequences that
in experimental models produces glomerular injury but
only limited humoral responses [21, 22] have begun to
alter thinking on what role sensitized cells are playing in
organ specific autoimmune renal disease [23]. A role for
cell-mediated effector mechanisms independent of anti-
bodies in human Goodpasture’s disease is less well sub-
stantiated, perhaps at least in part because of the dual role
for CD4+ cells in the immune system in directing B-cell
responses and at sites of tissue immune injury, as effector
cells capable of recruiting macrophages and other effec-
tor cells.
The availability of mice that have been rendered ge-
netically deficient in different components of the immune
system has enabled a more precise and detailed study of
the mechanisms of the development of autoimmunity and
renal injury. In the current studies, EAG was induced in
C57BL/6 mice with intact B cells and antibody production
and in mice deficient in the membrane form of the l chain
(lT−/− mice) [24]. In lT−/− mice, B-cell development is
arrested at the pre-B-cell stage, but in heterozygous mice,
B-cell development and antibody production is normal,
due to allelic exclusion. Following this study, passive anti-
GBM was induced by transferring sera with isologous
anti-GBM antibodies from antibody-intact and antibody-
deficient mice with glomerulonephritis into RAG-1−/−
mice that lack all mature T and B cells [25]. To assess the
potential for antibodies generated independently of an
autoimmune process, sera from immunised Col4a3−/−
mice genetically deficient in the Goodpasture antigen
[26] were transferred into RAG-1−/− mice. Together, the
studies demonstrate that both cell mediated processes
and anti-GBM antibodies can induce renal injury in au-
toimmune anti-GBM glomerulonephritis.
METHODS
Mice and a3-a5(IV)NC1 dimers
To investigate the role of B cells and antibody pro-
duction in EAG, lT−/− mice (created using gene target-
ing to disrupt the membrane exon of the gene encoding
the l chain constant region of the IgM molecule [24])
were used. T-cell function is normal in lT−/− mice [27].
The phenotype of mice was confirmed by flow cytomet-
ric analysis of B220 (CD45R) [10]. Fluorescein isothio-
cyanate (FITC)-conjugated rat antimouse CD45R/B220
monoclonal antibody (RA2.6B23) (Pharmingen, San
Diego, CA, USA) (dilution 1:30) detected B220-
positive circulating B cells and R-phycoerythrin (R-PE)-
conjugated rat antimouse CD4 monoclonal antibody
(GK1.5) (Pharmingen) (dilution 1:300) was used as
a positive control to detect CD4+ cells. Wild-type
C57BL/6 mice (Monash University Central Animal Ser-
vices, Clayton, Victoria, Australia) and littermate lT+/−
mice served as B-cell–intact controls. Recombination ac-
tivating gene-1 (RAG-1−/−)-deficient mice (C57BL/6
background) (bred in Monash Medical Center Specific
Pathogen-Free Facility) fail to produce mature T or B
lymphocytes [25]. Col4a3−/− mice (Jackson Laborato-
ries, Bar Harbor, ME, USA) (bred at Central Animal
Services, Monash University) [26] on a mixed C57BL/6 ×
129Sv/J background were identified by genotyping off-
spring of Col4a3+/− parents.
The immunogen, the a3-a5(IV)NC1 heterodimer, was
isolated from bovine testis basement membrane, which
is enriched in the a3(IV) chain of type IV collagen
compared to GBM [28]. These dimers have been used
to induce EAG in mice and rabbits [18, 29, 30]. The
a3(IV)NC1 domain, isolated by collagenase digestion of
basement membrane, has been recently defined as ex-
isting mainly as a heterodimer composed of the a3 and
a5 NC1 domains [31]. This a3-a5(IV)NC1 heterodimer
was purified by C18 reverse-phase chromatography [28]
followed by treatment with 6 m guanidine hydrochloride
(GuHCl) (MP Biomedicals, Irvine, CA, USA) and by gel
filtration chromatography on a TSK SW column (Agilent
Technologies, Palo Alto, CA, USA) to resolve the dimers
from monomers [32].
Experimental design
EAG was induced in 4- to 6-week-old male mice by
intraperitoneal injection of Bordatella pertussis antigen
(Bioscientific, Gymea, NSW, Australia) containing 5.1 ×
108 killed Bordetella pertussis in 200 lL saline, followed by
25 lg a3-a5(IV)NC1 heterodimers in 100 lL of Freund’s
complete adjuvant (FCA) subcutaneously at the base of
the tail. Four weeks later, mice were boosted with a fur-
ther 25 lg of heterodimers in FCA subcutaneously. Renal
injury and immune responses were studied 12 weeks after
the first immunization. The following mice were studied:
B-cell–intact lT+/+ mice (N = 9), B-cell–intact lT+/−
mice (N = 3), and B-cell–deficient lT−/− mice (N =
6). One group of normal lT+/+ mice (N = 6) received
immunizations and boosting with equivalent doses and
volumes of B. pertussis antigen and FCA alone, without
a3-a5(IV)NC1 heterodimers. Histologic assessments
were performed on randomly selected slides read in a
blinded (masked) fashion.
568 Dean et al: Cells and antibodies in experimental autoimmune Goodpasture’s disease
Four groups (N = 3 to 4 each group) of RAG-1−/−
mice aged 11 to 12 weeks received 250 lL of pooled
sera each, administered via intravenous injection. The
first group received sera from diseased lT+/+ mice im-
munized with a3(IV)NC1/FCA (+/+glomerulonephritis
→ RAG-1−/−). Two negative controls were employed.
First, sera from a3-a5(IV)NC1/FCA-sensitized lT−/−
mice (sera in the absence of any antibody) was transferred
into RAG-1−/− mice (−/−glomerulonephritis → RAG-
1−/−). Second, sera from nonsensitized lT+/+ donor
mice without glomerulonephritis demonstrated the ef-
fect of transfer of normal sera into RAG-1−/− recipi-
ent mice (+/+no glomerulonephritis → RAG-1−/−). A
further group received sera from Col4a3−/− mice immu-
nized with a renal basement membrane (RBM) prepara-
tion (Col4a3−/− → RAG-1−/−) using a modification of
a previously published method [33]. The RBM prepara-
tion was derived from kidney cortex of normal C57BL/6
mice, homogenized then centrifuged (2500g, 10 minutes).
Following washing, sonication and lysis, membranes were
collected by centrifugation, then digested with type I col-
lagenase (Sigma Chemical Co., St. Louis, MO, USA). For
experiments involving transfer of sera from Col4a3−/−
mice, 6-week-old mice were immunized with a total of
1.5 mg of collagenase solubilized material in three di-
vided doses intraperitoneally over a 3-week period, ini-
tially in FCA and subsequently in FIA. Sera were ob-
tained 4 days after the final immunization. Twenty-four
hours after transfer of sera to RAG-1−/− mice, recip-
ient mice were placed on metabolic cages for 24-hour
urine collection, then humanely killed (48 hours after
passive transfer). Further experiments were performed
with a 6-day end point by transferring the same quan-
tity of sera from diseased lT+/+ mice immunized with
a3-a5(IV)NC1/FCA or from nonsensitized lT+/+ mice,
again into RAG-1−/− mice. Results are expressed as the
mean ± SEM. The significance of differences between
groups was determined by t test for two groups or, for
multiple groups by analysis of variance (ANOVA) with
Tukey’s post hoc test.
Assessment of renal injury
Kidney tissue was fixed in Bouin fixative, embedded in
paraffin, and 3 lm tissue sections were cut and stained
with periodic acid-Schiff (PAS) reagent. The proportion
of glomeruli affected was determined by examining a
minimum of 50 glomeruli per mouse for abnormalities
according to a previously published method [34]. Abnor-
malities included crescent formation (two or more lay-
ers of cells in Bowman’s space), segmental proliferation,
necrosis, or hyalinosis or capillary wall thickening. Total
glomerular cell nuclei were counted in a minimum of 20
glomeruli per mouse and results were expressed as cells
per glomerular cross-section (c/gcs).
Urinary creatinine concentrations were measured by
the alkaline picric acid method using an autoanalyzer.
Serum creatinine concentrations at the end of experi-
ments were measured by an enzymatic creatininase as-
say. Urinary protein excretions were determined by the
Bradford method [35] on 24-hour urine collections from
mice prior to disease and from each mouse over the final
24 hours of the experiment. The urinary protein excretion
was expressed in milligrams of protein per 24 hours.
Assessment of immune responses and immune effectors
in glomeruli
Tissue was embedded in Optimal Cutting Tempera-
ture Compound, frozen in liquid nitrogen, and stored at
−70◦C. Snap-frozen tissue sections (6 lm) were stained
for mouse immunoglobulin using FITC-sheep antimouse
immunoglobulin (Silenus, Hawthorn, Victoria, Australia)
(1:100). Indirect immunofluorescence was performed us-
ing kidney sections from unmodified lT−/− mice to elim-
inate background staining, using sera (1:10) (overnight
4◦C) then the detecting antibody for 1 hour. Quantitative
evaluation of the extent of glomerular antibody deposi-
tion was made by capturing images of at least 10 random
glomeruli at high power from each mouse and analyz-
ing mean fluorescence intensity in each glomerular tuft
by tracing each tuft, after removing background values
(i.e., light emanating from stained section without tissue)
for each slide (NIH Image, Bethesda, MD, USA). Dif-
ferent capture camera settings were used for comparing
immunoglobulin deposition in group of mice with active
disease and comparing antibody deposition in active ver-
sus passive transfer studies. Values are expressed as arbi-
trary units (AU) of fluorescence per pixel.
Titers of mouse anti-GBM were measured by enzyme-
linked immunosorbent assay (ELISA) on serum col-
lected at the end of experiments. Plates were coated
with 10 lg/mL bovine a3-a5(IV)NC1, washed, blocked
[1% bovine serum albumin (BSA)], washed, then incu-
bated with mouse serum (1:400 and 1:1200) (overnight
4◦C). Bound mouse immunoglobulin was detected with
horseradish peroxidase-conjugated sheep antimouse
immunoglobulin (Amersham, Little Chalfont, UK)
(1:2000). 0.1 mol/L 2,2′-azino-di-3-ethylbenzthiazoline
sulfonate (ABTS) (Boehringer Mannheim, Germany)
substrate solution was added and the absorbance read
at 405 nm.
For detection of leucocytes in glomeruli, snap-frozen
tissue sections (6 lm) were stained with GK1.5 (an-
timouse CD4) [American Type Culture Collection
(ATCC), Manassas, VA, USA] and M1/70 (anti-Mac-
1, which recognizes macrophages and neutrophils)
(ATCC). GK1.5 and M1/70 were coupled to Alexa Fluor
dye 594 (Molecular Probes, Eugene, OR, USA). Sec-
tions were incubated at a dilution of 1:20 (including 10%
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Fig. 1. lT+/+ and lT+/− mice have intact B cells (A and B) by flow cytometry and humoral responses. They make antibodies to the disease-
initiating antigen (D) by enzyme-linked immunosorbent assay (ELISA) detecting serum immunoglobulin against a3-a5(IV)NC1 dimers, that bind
to the glomerular basement membrane (GBM) in a linear fashion (E and F). lT−/− mice have no B cells (C), no serum antibody against a3-
a5(IV)NC1 (D), and do not exhibit antibodies that bind to the GBM (G). Data are expressed as the mean ± SEM. GN is glomerulonephritis; OD
is optical density.
normal rat serum) for 1 hour. A minimum of 20 glomeruli
were assessed per animal for both GK1.5 and M1/70 and
results were expressed as c/gcs. Complement was assessed
by using FITC-goat antimouse C3 (Cappel, Durham, NC,
USA) antibodies at dilutions of 1 in 25, 1 in 50, and 1
in 100. As a positive control for C3 staining, renal tis-
sue from a BALB/c mouse with accelerated autologous
anti-GBM glomerulonephritis, a nonautoimmune model
of glomerular injury where glomerular C3 deposition is
prominent [36] was used.
RESULTS
Renal injury in EAG occurs in the absence of B cells and
circulating antibody
B-cell and antibody-deficient lT−/− mice were iden-
tified by phenotypic analysis of whole blood from indi-
vidual animals. While lT−/− mice had no B220+ cells,
lT+/− and lT+/+ mice had normal proportions of
B220+ cells (Fig. 1A to C). When immunized with a3-
a5(IV)NC1 dimers, lT+/− and lT+/+ mice made equiv-
alent amounts of antigen-specific antibodies (Fig. 1D),
and both lT+/− and lT+/+ mice developed linear de-
position of immunoglobulin on the GBM (Fig. 1E and
F) and to a lesser degree the tubular basement mem-
brane (TBM). There was a similar intensity of fluores-
cence assessed quantitatively from mouse antibodies on
the GBM between lT+/+ (66.6 ± 5.7 AU/pixel) and
lT+/− mice (54.5 ± 9.2 AU/pixel). lT−/− deficient
mice had no serum antigen-specific antibodies [their val-
ues were below baseline values for normal mice that
had not been immunized with a3-a5(IV)NC1 dimers
(Fig. 1D) and no deposition of immunoglobulin on the
GBM (Fig. 1G) fluorescence value 5.2 ± 1.1 AU/pixel].
Given their equivalent phenotype, lT+/+ and lT+/−
mice were considered as a single group of B-cell–intact
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Fig. 2. Both B-cell–intact and B-cell–deficient mice develop renal in-
jury in experimental autoimmune glomerulonephritis (EAG). Both
antibody-deficient and antibody-intact mice developed similar numbers
of abnormal glomeruli (A), glomerular hypercellularity (B), glomeru-
lar CD4+ cells (C), and Mac-1+ cells (D). The dotted lines represent
mean values for mice immunized with adjuvant alone that did not de-
velop glomerulonephritis. Data are expressed as the mean ± SEM.
mice. Both B-cell–intact mice and B-cell–deficient mice
immunized with a3-a5(IV)NC1 dimers developed prolif-
erative glomerulonephritis, with a significant proportion
of abnormal glomeruli, glomerular hypercellularity, and
occasional crescent formation (Figs. 2 and 3). Crescent
formation was present in 1.3 ± 0.4% of glomeruli in B-
cell–intact mice with EAG and 3.0 ± 1.1% of glomeruli
in B-cell–deficient mice with EAG. Some mice from each
group showed occasional periglomerular leukocytes and
a few mice demonstrated perivascular infiltrates.
The absence of B cells, circulating immunoglobulin,
and glomerular deposition of antibody did not diminish
the degree of renal histologic injury, including the per-
centage of affected glomeruli (Fig. 2A), total glomeru-
lar cell numbers (Figs. 2B and 3A and B), and the pres-
ence of occasional glomerular crescents (Fig. 3C and D).
The renal tubulointerstitium was well preserved in both
groups of mice. Both B-cell–intact and B-cell–deficient
mice had similar numbers of CD4+ T cells and M1/70-
positive cells in glomeruli (Fig. 2C and D). Complement
(C3) was present in glomeruli of B-cell–intact mice, with
a interrupted linear pattern that was in some mice (50%)
segmental. However, C3 was not present in glomeruli of
B-cell–deficient mice. As a further control, B-cell–intact
mice immunized with adjuvant without a3-a5(IV)NC1
dimers did not develop histologic injury (all ANOVA)
(P < 0.001 versus B-cell–intact and B-cell–deficient
groups with glomerulonephritis) in the form of glomeru-
lar hypercellularity [28.2 ± 0.8 c/gcs (normal mice
28.8 ± 2.3 c/gcs)], any glomerular crescents, only a small
proportion of abnormal glomeruli (6.3% ± 0.8%) and did
not develop significant glomerular leucocyte infiltration
(CD4+ cells 0.11 ± 0.01 c/gcs and M1/70+ cells 0.17 ±
0.05 c/gcs). Mice with EAG developed a similar degree of
proteinuria whether or not B cells were present (Fig. 4),
but proteinuria did not develop over 12 weeks in mice
immunized with adjuvant alone (data not shown). Serum
creatinine values were normal and similar in both B-cell–
intact and B-cell–deficient mice (B-cell–intact glomeru-
lonephritis 12.6 ± 1.1 lmol/L, B-cell–deficient glomeru-
lonephritis 14.6 ± 3.6 lmol/L, and B-cell–intact FCA
alone 14.8 ± 1.2 lmol/L). Calculation of creatinine clear-
ances showed similar results (data not shown).
Transfer of isologous anti-GBM antibodies
to RAG-1−/− mice induces proteinuria
To determine whether isologous circulating antibodies
against the GBM would induce renal injury, sera from
B-cell–intact mice with glomerulonephritis was trans-
ferred to RAG-1−/−mice that lack mature and functional
T and B cells (+/+glomerulonephritis → RAG-1−/−).
Both indirect immunofluorescence using sera from donor
mice and direct immunofluorescence of kidneys from
recipient RAG-1−/− mice demonstrated linear staining
with sera from B-cell–intact mice with glomerulonephri-
tis (Fig. 5A and B) or using sera from Col4a3−/− mice
immunized with a murine RBM preparation (Col4a3−/−
→ RAG-1−/−) (Fig. 5C and D) but not with sera from
either B-cell–deficient mice with glomerulonephritis (i.e.,
disease but no antibodies, −/−glomerulonephritis →
RAG-1−/−) (Fig. 5E and F) or from normal C57BL/6
mice without anti-GBM antibodies or disease (i.e., an-
tibodies but no disease, +/+no glomerulonephritis →
RAG-1−/−) (Fig. 5G and H). Faint nonlinear tuft stain-
ing was observed in direct immunofluorescence from
RAG-1−/− mice receiving nonimmune sera from normal
C57BL/6 mice (Fig. 5H) that is likely to reflect reconsti-
tution of these antibody-deficient mice with normal im-
munoglobulins with passive and mild antibody deposition
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Fig. 3. Histological injury in mice with experimental autoimmune glomerulonephritis (EAG). C57BL/6 mice that received Bordetella pertussis
antigen and Freund’s complete adjuvant (FCA) alone, without a3-a5(IV)NC1 heterodimers did not develop histologic injury (A, D, and G), in
contrast to a3-a5(IV)NC1 heterodimer immunized mice. Both B-cell–intact mice (B, E, and H) and B-cell–deficient mice (C, F, and I) developed
EAG with proliferative glomerulonephritis (B, C, H, and I) and an occasional glomerular crescent (E and F). In control injected mice, the larger
juxtamedullary glomeruli did not exhibit proliferation or matrix accumulation (G), unlike a3-a5(IV)NC1 heterodimer immunized B-cell–intact
(H) or B-cell–deficient mice (I) mice [periodic acid-Schiff (PAS) stain original magnification ×200] [(G to H) shown at higher final magnification].
in glomeruli. Quantitation of immunoglobulin deposition
in +/+glomerulonephritis → RAG-1−/− (N = 4) mice
compared with six randomly selected lT+/+ mice with
active disease showed that recipients of transferred sera
had less IgG deposition in glomeruli than mice with ac-
tive disease (lT+/+ active disease 132.1 ± 12.0 AU/pixel
versus +/+glomerulonephritis → RAG-1−/− 71.4 ± 6.3
AU/pixel) (P < 0.01) (t test).
Two days after transfer, proteinuria had developed in
mice receiving sera from B-cell–intact mice with glomeru-
lonephritis (+/+glomerulonephritis → RAG-1−/−), but
not in mice receiving sera from either B-cell–deficient
mice with glomerulonephritis or from normal C57BL/6
mice without anti-GBM antibodies (Fig. 6A). Transfer of
sera from murine RBM immunized Col4a3−/− mice to
RAG-1−/− mice resulted in similar appearances and sim-
ilar urinary protein excretion to +/+glomerulonephritis
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Fig. 4. Proteinuria in B-cell–intact and B-cell–deficient mice with ex-
perimental autoimmune glomerulonephritis (EAG). Proteinuria was
similar in both B-cell–intact and B-cell–deficient mice. ∗P < 0.05 vs.
predisease induction (t test). Data are expressed as the mean ± SEM.
→ RAG-1−/− mice. Histologic analyses revealed no sig-
nificant cellular proliferation and only a small propor-
tion (∼10%) of glomeruli affected (Fig. 6B and C). Renal
function was not impaired (data not shown), complement
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Fig. 5. Indirect and direct immunofluorescence findings in passive
transfer studies. Serum from B-cell–intact mice with glomerulonephritis
(A and B) or Col4a3−/− mice immunized against renal basement mem-
branes (C and D), but not B-cell–deficient mice with glomerulonephritis
(E and F) or unimmunized B-cell–intact mice without glomerulonephri-
tis (G and H), induces linear staining on the glomerular basement mem-
brane (GBM) of RAG-1−/− recipients (A, C, E, and G) indirect im-
munofluorescence using unmodified lT−/− mouse kidney sections; (B,
D, F, and H) direct immunofluorescence in RAG-1−/− recipients.
(C3) deposition was not observed in mice receiving sera
from B-cell–intact mice with glomerulonephritis consis-
tently above background staining seen in normal mice
without glomerulonephritis (dilutions 1:25, 1:50, or 1:100)
and significant accumulation of effector M1/70+ cells in
glomeruli (+/+glomerulonephritis → RAG-1−/− 0.32 ±
0.04 c/gcs) or within the interstitium was not observed at
48 hours.
Further passive antibody transfer experiments into
RAG-1−/− mice showed that by day 6, urinary pro-
tein excretion had normalised in mice receiving sera
from B-cell–intact mice with glomerulonephritis (day 6
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Fig. 6. Proteinuria and glomerular findings in RAG-1−/− mice 48
hours after passive transfer of anti-glomerular basement membrane
(GBM) antibodies. RAG-1−/− mice receiving sera from B-cell–intact
mice with glomerulonephritis (GN) (+/+GN → RAG-1−/−) or from
Col4a3−/− mice immunized with a renal basement membrane prepa-
ration (Col4a3−/− → RAG-1−/−) developed proteinuria (A). Nega-
tive controls included sera from lT−/− mice with glomerulonephritis
(−/−GN → RAG-1−/−) and sera from unimmunized antibody-intact
genetically normal mice (+/+no GN → RAG-1−/−). Major histologic
abnormalities were not present in mice (B and C). ∗P < 0.05 compared
with both negative control groups [analysis of variance (ANOVA)].
Data are expressed as the mean ± SEM.
+/+glomerulonephritis → RAG-1−/− 0.75 ± 0.22 mg/24
hours and day 6 +/+no glomerulonephritis → RAG-
1−/− 1.10 ± 0.30 mg/24 hours). Histologic appearances
showed no overall progression of injury in mice (day 6
+/+glomerulonephritis → RAG-1−/− 13.0 ± 1.7% ab-
normal glomeruli and day 6 +/+no glomerulonephritis →
RAG-1−/− 7.7 ± 1.7% abnormal glomeruli), again with
no significant C3 deposition and only 0.50 ± 0.10 M1/70+
c/gcs. Occasional glomeruli in three out of four day
6 +/+glomerulonephritis → RAG-1−/− mice showed
glomerular crescent formation (1.2 ± 0.5% glomeruli
affected).
DISCUSSION
Autoimmune anti-GBM is a classic example of an au-
toimmune disease that predominantly targets an antigen
within the kidney [1]. While considered predominantly an
antibody-mediated disease, recent evidence suggests that
cell-mediated processes can also significantly contribute
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to renal injury in this disease [11, 17, 18, 20–23, 37–39]. Ev-
idence from experimental models of other immune renal
diseases suggests variable requirements for B cells and
immunoglobulins as well as the variable participation of
cell-mediated effectors [10, 13, 14, 36, 40–42].
The current studies use a model of experimental au-
toimmune Goodpasture’s disease in mice induced by
immunization with a3-a5(IV)NC1, the target antigen
in human anti-GBM glomerulonephritis, to address the
roles of cellular and humoral effectors in renal organ spe-
cific autoimmunity. Using an active model they demon-
strate that histologic and functional injury can occur
in the absence of mature B cells and immunoglob-
ulin. B-cell–deficient mice developed proteinuria and
abnormal renal histology, together with a T cell and
macrophage/neutrophil infiltrate in glomeruli. The find-
ing that renal injury can occur in this autoimmune disease
in the absence of immunoglobulin highlights a potential
key role for cell-mediated processes involving effector
CD4+ cells and macrophages and potentially CD8+ cells
(also found in this lesion [29]) in EAG. Our approach, by
demonstrating injury in the absence of B cells and cir-
culating antibody in mice immunized with the Goodpas-
ture’s antigen, lends weight to other studies implicating
cell-mediated effector responses in renal injury in experi-
mental autoimmune Goodpasture’s disease. Approaches
used by other studies have ranged from observations
that some peptides or peptide sequences derived from
a3(IV)NC1 induce glomerulonephritis with only limited
humoral reactivity [21, 22], to cell transfer studies [18,
20], to CD8 depletion reducing disease while not affecting
anti-GBM antibodies [11], to the induction of glomeru-
lonephritis in bursectomized chickens [17].
The evidence that cell-mediated effectors are relevant
in human Goodpasture’s disease is less clear. CD4+ cells
function as key helper cells in B-cell responses. Therefore
the demonstration that CD4+ cells react with peptides
from or with the whole a3(IV)NC1 molecule [43–45] may
indicate only that CD4+ cells are relevant to B-cell help
and antibody production in Goodpasture’s disease. Re-
cent data showing CD4+ cells from patients with active
Goodpasture’s produce interferon-c (IFN-c( [and switch
to interleukin (IL)-10 production when disease is inac-
tive] support a role for these cells as effectors [45]. How-
ever, while IFN-c activates macrophages, it also plays a
role in IgG subclass switching to more complement fixing
and macrophage recruiting (by Fc-Fcc receptor interac-
tions) subclasses. Some evidence that cell-mediated pro-
cess may be important in human Goodpasture’s disease
comes from studies showing CD4+ and CD8+ cells in
crescentic glomeruli [37, 38] and from the demonstration
of autoreactive CD8+ cells from humans with Goodpas-
ture’s disease [39].
Passive transfer of serum containing isologous anti-
GBM antibodies from B-cell–intact mice with EAG into
RAG-1−/− mice, but not from B-cell–deficient mice with
EAG or from B-cell–intact mice without EAG, induced
proteinuria at 48 hours. Significant C3 deposition did not
occur, suggesting that complement-mediated injury was
not prominent. There were few macrophages/neutrophils
per glomerulus at 48 hours in mice receiving serum from
antibody-intact mice with EAG. While it is possible that
the proteinuria at 48 hours had been induced by transient
intraluminal accumulation of activated macrophages or
neutrophils, studies in intact animals and also in an iso-
lated perfused kidney system have shown that antibodies
can induce proteinuria by binding to the GBM and dis-
rupting its size/charge selectivity in the absence of com-
plement and effector cells [6–8]. Quantitative analysis of
glomerular immunoglobulin deposition showed that less
immunoglobulin was deposited in passive transfer exper-
iments than in active disease. It is possible that comple-
ment and effector leukocytes such as macrophages and
neutrophils may have played a more prominent role if
higher doses of sera and/or multiple doses of sera had
been able to be transferred. A similar pattern of im-
munoglobulin deposition and injury was induced by sera
from Col4a3−/− mice immunized with a RBM prepara-
tion. By 6 days, proteinuria had subsided in mice given
anti-GBM antibodies (day 6 +/+glomerulonephritis →
RAG-1−/−). There was little evidence of disease pro-
gression although an occasional crescent was observed
in three of four mice. This data is concordant with that
of Kalluri et al [18] who stated that injury could be in-
duced by transferred antibody, and with that of Sado,
Naito, and Okigaki [46]. In the former study, injury in-
duced by isologous antibodies was only severe in mice
with an intact T-cell receptor and in the latter study rel-
atively severe injury occurs some days after transfer into
Wistar-Kyoto/NCrj rats with intact cellular immunity. The
current studies are also consistent with both early and
more recent data that used human anti-GBM antibod-
ies in monkeys [15] and mice [47], respectively. In these
studies there is the potential for heterologous antibody
induced injury that may differ from isologous/autologous
antibody-induced disease [4] and/or which may involve
immune reactions to the heterologous globulin as a for-
eign antigen, as occurs in the “planted antigen” models of
“anti-GBM glomerulonephritis” [9]. In our current stud-
ies, the absence of adaptive immunity in RAG-1−/− mice
and the transfer of isologous antibodies with controls that
include diseased mice without antibodies demonstrate a
role for immunoglobulin alone in this disease. The use
of sera from immunized Col4a3−/− mice to induce pro-
teinuria in RAG-1−/− mice demonstrates nephritogenic
isologous antibodies to the GBM can be generated in-
dependent of an autoimmune process and suggests that
these mice may be a suitable tool for modeling post-
transplant alloantibody production in patients with Al-
port syndrome.
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CONCLUSION
These studies demonstrate that in the absence of B
cells and immunoglobulin, cell-mediated processes are
capable of inducing renal injury in EAG induced by the
same antigen responsible for human anti-GBM glomeru-
lonephritis. Passive transfer studies showed that sera
from mice with glomerulonephritis containing autolo-
gous antibodies can induce proteinuria. Therefore, both
cell-mediated processes and humoral mechanisms induce
injury in anti-GBM glomerulonephritis.
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